ÈËÆÞÖгöÊÓƵ

Jessica Ann Walsh
( out of 43 reviews )

Jessica Ann Walsh, MD

Languages spoken: English

Clinical Locations

ÈËÆÞÖгöÊÓƵ of Utah Hospital

Rheumatology, Area E
Salt Lake City
801-581-7724

  • Jessica Walsh, MD, is an Associate Professor at the ÈËÆÞÖгöÊÓƵ of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.




    Walsh received her Medical Degree and Rheumatology training from the ÈËÆÞÖгöÊÓƵ of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Rheumatology)

    Patient Rating

    4.9 /5
    ( out of 43 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    June 07, 2024
    UH HOSPITALS AND CLINICS

    As I said, Dr. Walsh treats the whole patient. She remembers things about me and my life, and she watches for ways or treatments that may improve my life. I think she is an excellent doctor!

    June 02, 2024
    UH HOSPITALS AND CLINICS

    Dr Walsh is a very caring Dr. I feel that she really listens to my challenges and works to find the best resolutions, including me in all options, and we decide together which things to utilize in finding the best things to help me.

    May 10, 2024
    UH HOSPITALS AND CLINICS

    Dr. Jessica Walsh is absolutely a Class Act. She spent so much personal time with me. She educates me each time we see each other. I trust her with my life and she's pulled me through some tough times. She truly is wonderful and very thorough.

    May 03, 2024
    UH HOSPITALS AND CLINICS

    The The assistant was very nice and she she explained everything to me so I can understand.

    March 08, 2024
    UH HOSPITALS AND CLINICS

    Very professional and pleasant. Thanks for your kind attention.

    March 02, 2024
    UH HOSPITALS AND CLINICS

    Dr Walsh is the best! She listens to my concerns and addresses them directly. She monitors my symptoms and helps me deal with them. Can you hire more doctors like her?

    March 01, 2024
    UH HOSPITALS AND CLINICS

    Dr Walsh is amazingly talented and focused on the role of my care. She has helped me more than I can ever say. Thank you for your dedication to your profession.

    February 24, 2024
    UH HOSPITALS AND CLINICS

    She is the BEST in the business. She gives ÈËÆÞÖгöÊÓƵcare a good name in a day and age when others don't. She is so knowledgeable, yet takes time and listens to me. I do not know what I would do with my medical problems if it were not for her and her staff!

    February 04, 2024
    UH HOSPITALS AND CLINICS

    Dr. Walsh is my favorite dr. So caring and listens to me. She personifies what every dr should be. Great bedside manners, yet is very efficient.

    See More Patient Comments

  • Jessica Walsh, MD, is an Associate Professor at the ÈËÆÞÖгöÊÓƵ of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.




    Walsh received her Medical Degree and Rheumatology training from the ÈËÆÞÖгöÊÓƵ of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Dermatology -Adjunct
    Academic Divisions Rheumatology
    Board Certification
    American Board of Internal Medicine (Sub: Rheumatology)

    Education history

    Graduate Training Clinical Investigation - ÈËÆÞÖгöÊÓƵ of Utah M.S.C.I
    Rheumatology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Fellow
    Chief Resident Internal Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Resident
    Internal Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident
    Internship Internal Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Intern
    Medicine - ÈËÆÞÖгöÊÓƵ of Utah M.D.
    Graduate Training Business Administration - Boise State ÈËÆÞÖгöÊÓƵ M.B.A.
    Biology - Whitman College B.A.

    Selected Publications

    Journal Article

    1. Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, Kianifard F, Elam C, Bommidi GM, Winseck A, Gensler LS (2024). A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). ()
    2. Nowell WB, Gavigan K, Garza K, OBeirne R, Safford M, George M, Ogdie A, Walsh JA, Danila MI, Venkatachalam S, Stradford L, Rivera E, Curtis JR (2024). Which Educational Topics and Smartphone App Functions Are Prioritized by US Patients With Rheumatic and Musculoskeletal Diseases? A Mixed-Methods Study. J Rheumatol. ()
    3. Baraliakos X, Saffore CD, Collins EB, Parikh B, Ye X, Walsh JA (2024). Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria. Rheumatol Ther. ()
    4. Walsh JA, Pei S, Alexander S, Braaten T, Walker JH, Clewell J, Douglas KM, Penmetsa GK, Ye X, Breviu B, Cannon GW, Kunkel GA, Sauer BC (2024). Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Semin Arthritis Rheum, 66, 152436. ()
    5. Carroll C, Aalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Measuring Psoriasis Severity at Home. J Vis Exp, (205). ()
    6. Walsh JA, Saffore CD, Collins EB, Ostor A (2023). Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther, 10(5), 1385-1398. ()
    7. Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng BJ (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis Care Res (Hoboken). ()
    8. Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther, 10(4), 887-899. ()
    9. Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, Khan MA (2023). The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. ACR Open Rheumatol, 5(5), 264-276. ()
    10. Baraliakos X, Ranza R, str A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A (2023). Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther, 25(1), 56. ()
    11. Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA (2023). Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res (Hoboken). ()
    12. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry. Arthritis Rheumatol, 75(2), 232-241. ()
    13. Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine, 105534. ()
    14. Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm, 29, 1-12. ()
    15. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as biomarkers in axial spondyloarthritis: observational studies from the PULSAR registry. Arthritis Rheumatol, 75(2), 232-241. ()
    16. Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A (2022). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. J Rheumatol.
    17. Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A (2022). Impact of Fatigue on ÈËÆÞÖгöÊÓƵ-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol, 49, 1221-1228. ()
    18. Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J (2021). Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open, 8(2). ()
    19. van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M (2022). Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther, 39(6), 2806-2819. ()
    20. Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh J (2022). Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. Rheumatol Ther, 9(2), 663-677. ()
    21. Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J (2022). Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatol Ther, 9(2), 735-751. ()
    22. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Calderon DMS, Kiltz U (2022). Improvement of Functioning and ÈËÆÞÖгöÊÓƵ With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken), 74(3), 451-460. ()
    23. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119. ()
    24. Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh JA (2021). Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. Rheumatol Ther, 9, 509-520. ()
    25. Walsh JA, Magrey M (2020). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J Clin Rheumatol, 27(8), e547-e560. ()
    26. Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J (2021). Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol, 40(12), 4933-4942. ()
    27. Nowell WB, Gavigan K, Hunter T, Malatestinic WN, Bolce RJ, Lisse JR, Himelein C, Curtis JR, Walsh JA (2021). Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatol, 4, 85-94. ()
    28. Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, Clegg DO, Dubreuil M, Kaushik P, Ng B, Chang E, Duong R, Park J, Kerr GS (2021). Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int, 42, 1925-1937. ()
    29. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565. ()
    30. Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol, 40(9), 3667-3677. ()
    31. Wan MT, Walsh JA, Craig ET, Husni ME, Scher JU, Reddy SM, Leung YY, Ogdie A (2020). A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology (Oxford), 60(5), 2307-2316. ()
    32. Walsh JA, Pei S, Penmetsa GK, Overbury RS, Clegg DO, Sauer BC (2020). Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research. J Rheumatol, 48(5), 685-692. ()
    33. Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD (2021). Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Adv Ther, 38(5), 2353-2364. ()
    34. Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun J (2020). Ixekizumab Improves Functioning and ÈËÆÞÖгöÊÓƵ in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. J Rheumatol, 48(2), 188-197. ()
    35. Magrey MN, Danve AS, Ermann J, Walsh JA (2020). Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc, 95(11), 2499-2508. ()
    36. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Marcelino Sandoval Calderon D, Kiltz U (2020). Ixekizumab Improves Functioning and ÈËÆÞÖгöÊÓƵ in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. Arthritis Care Res (Hoboken), 74, 451-460. ()
    37. Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, Ogdie A (2019). Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. J Rheumatol, 47(10), 1496-1505. ()
    38. Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD (2020). Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin, 36(7), 1245-1252. ()
    39. Overbury RS, Pei S, Breviu B, Clegg DO, Walsh JA (2020). Obstructive sleep apnea and fatigue in patients with inflammatory arthritis taking TNF-inhibitors. Int J Clin Rheumtol, 15(3), 38.
    40. Haberman RPerez-Chada LMSiegel EReginato AMWebster DChandran VWalsh JRosen CFReddy SOgdie AScher JUMerola JF (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. Rheumatol Int, 5(2), 68-72. ()
    41. Haberman R, Perez-Chada L, Siegel E, Reginato A, Webster D, Chandran V, Walsh JA Rosen C, Reddy S, Ogdie A, Scher J, Merola J (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. J Psoriasis Psoriatic Arthritis.
    42. Dougados M, Wei JC, Landew R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis, 79(2), 176-185. ()
    43. Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer BC (2019). Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. J Rheumatol, 47(1), 42-49. ()
    44. Deodhar A, Gensler LS, Magrey M, Walsh JA, Winseck A, Grant D, Mease PJ (2019). Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. Rheumatol Ther, 6(4), 487-501. ()
    45. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. ()
    46. Farahi JM, Lynn D, Anand P, Walsh JA, Hashim M, Duong R, Dellavalle RP, Reimold A, Kerr GS, Richards JS, Chang E, Kaushik P, Dubreuil M, Caplan L (2019). A Prospective Cross-Sectional Analysis of Construct Validity for the PALMPASS, A Brief Patient-Reported Outcome Measure for Psoriasis. J Psoriasis Psoriatic Arthritis, 4(4), 186-191. ()
    47. Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R (2019). Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC Rheumatol, 3, 39. ()
    48. Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther, 6(3), 435-450. ()
    49. Coit P, Kaushik P, Caplan L, Kerr G, Walsh JA, Dubreuil M, Reimold A, Sawalha A (2019). Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. J Autoimmun, 102, 126-132.
    50. Walsh JA, Rozycki M, Yi E, Park Y (2019). Application of machine learning in the diagnosis of axial spondyloarthritis. Curr Opin Rheumatol, 31(4), 362-367. ()
    51. Braaten TJ, Zhang C, Presson AP, Breviu B, Clegg DO, Walsh JA (2019). Gender Differences in Psoriatic Arthritis with Fatigue, Pain, Function and Work Disability. J Psoriasis Psoriatic Arthritis, 4(4), 192-197.
    52. Walsh JA, Song X, Kim G, Park Y (3/24/2019). Counting the Costs of Ankylosing Spondylitis. 2517(106), 82-85.
    53. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken), 71(1), 2-29. ()
    54. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol, 71(1), 5-32. ()
    55. Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol, 37(12), 3285-3296. ()
    56. Walsh JA, Song X, Kim G, Park Y (2018). ÈËÆÞÖгöÊÓƵcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database. Rheumatol Ther, 5(2), 463-474. ()
    57. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. J Cardiol Cardiovasc Sci, 2(6), 17-23.
    58. Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A (2018). The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl), 8, 65-74. ()
    59. Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, Sauer BC (2018). Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC Musculoskelet Disord, 19(1), 317. ()
    60. Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P (2018). Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses form an Administrative Claims Database  . J Manag Care Spec Pharm, 24(7), 623-31. ()
    61. Walsh JA, Arledge T, Nurminen T, Peterson L, Stark J (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. J Rheumatol, 45(7), 922-928. ()
    62. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol, 37(7), 1869-1878. ()
    63. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm ÈËÆÞÖгöÊÓƵ Serv Res, 9(2), 115-121. ()
    64. Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gmez-Reino JJ, Aelion JA, ACTIVE investigators (2018). Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis, 77(5), 690-698. ()
    65. Walsh JA, Adejoro O, Chastek B, Park Y (2017). Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res, 7(4), 369-380. ()
    66. Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer BC (2017). Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol, 45(3), 430-436. ()
    67. Walsh JA, Tan H, Valdez H, Callis Duffin K (2017). Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity. J Psoriasis Psoriatic Arthritis, 2(4), 113-118.
    68. van der Heijde D, Dougados M, Landew R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford), 56(9), 1498-1509. ()
    69. Walsh JA, Shao Y, Leng J, He T, Teng CC, Redd D, Treitler Zeng Q, Burningham Z, Clegg DO, Sauer BC (2017). Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans. Arthritis Care Res (Hoboken), 69(9), 1414-1420. ()
    70. Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW (2016). Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ, 19(1), 34-43. ()
    71. Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K (2015). Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. Br J Dermatol, 173(1), 272-4. ()
    72. Walsh JA, Zhou X, Clegg DO, Teng C, Cannon GW, Sauer B (2015). Mortality in American Veterans with the HLA-B27 gene. J Rheumatol, 42(4), 638-44. ()
    73. Sieper J, Landew R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP (2014). Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol, 67(3), 668-77. ()
    74. Kinard K, Walsh JA, Penmetsa GK, Warner JEA (2014). Adalimumab and non-arteritic anterior ischaemic optic neuropathy: A case report. Neuroophthalmology, 38(5), 272-277. ()
    75. Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS (2013). Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res (Hoboken), 66(9), 1410-6. ()
    76. Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014). Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol, 41(8), 1670-4. ()
    77. Boehncke WH, Qureshi A, Merola JF, Thai D, Krueger GG, Walsh J, Kim N, Gottlieb AB (2013). Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol, 170(4), 772-86. ()
    78. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin KC (2013). Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol, 69(6), 931-7. ()
    79. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2012). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis, 72(6), 986-91. ()
    80. Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93. ()
    81. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999). Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol, 43(4), 269-76. ()

    Abstract

    1. Ogdie-Beatty A, Magrey M, Fitzsimmons R, Abdollahi S, Biljan A, Saffore C, Walsh JA (2021). Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic ÈËÆÞÖгöÊÓƵ System: A Retrospective Study [Abstract]. 73(suppl 10).
    2. Penmetsa GK, Pei S, Sauer BC, Douglas K, Walker J, Clewell J, Feng B, Walsh JA (2021). Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing [Abstract]. 73(suppl 10).
    3. Sen R, Kim E, Cheng E, Ganuthula K, Fang M, Kerr G, Walsh JA, Chang E, Raychaudhuri S, Reimold A, Caplan L (2021). A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio [Abstract]. 73(suppl 10).
    4. Breviu B, Pei S, Kirkpatrick M, Feng B, Walsh JA (2021). Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety [Abstract]. 73(suppl 10).
    5. Braaten T, Pei s, Rathod A, Penmetsa G, Douglas K, Walker J, Clewell J, Walsh JA (2021). Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans [Abstract]. 73(suppl 10).